^
3ms
Study on the mechanism of CXCL12/CXCR4-axis-mediated upregulation of IL-8 and IL-6 on the biological function of acute T lymphocyte leukaemia cells. (PubMed, Cytotechnology)
Treatment of cells with AMD3100, a CXCR4 antagonist, and G-CSF blocked the CXCL12/CXCR4 axis, inducing biological changes in the leukaemia cells and altering IL-8 and IL-6 levels...ELISA results confirmed that MG-132 (10 μm) inhibits IL-8 expression and that the NF-κB signalling pathway contributes to this effect...Treatment with SP600125, a Jun N-terminal kinase inhibitor, and Perifosine also inhibited IL-8 expression; however, this effect occurred later...IL-6 and IL-8 are physiologically regulated by the CXCL12/CXCR4 axis, while the NF-κB and JNK/AP-1 pathways are required for IL-8 expression in T-cell acute lymphoblastic leukaemia. Accordingly, by upregulating IL-8, the bone marrow microenvironment and CXCL12/CXCR4 axis may contribute to T-cell acute lymphoblastic leukaemia pathogenesis.
Journal
|
IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
CXCL8 expression • IL6 expression
|
MG132 • perifosine (D21266) • SP600125 • plerixafor
6ms
Germline PTEN genotype-dependent phenotypic divergence during the early neural developmental process of forebrain organoids. (PubMed, Mol Psychiatry)
Perifosine, an AKT inhibitor, reduced over-activated AKT and partially corrected the abnormalities in cellular organization observed in PTEN organoids...These findings demonstrate that different PTEN missense mutations can have a profound impact on neurodevelopment at diverse stages which in turn may predispose PHTS individuals to ASD. Further study will shed light on ways to mitigate pathological impact of PTEN mutants on neurodevelopment by stage-specific manipulation of downstream PTEN signaling components.
Journal
|
PTEN (Phosphatase and tensin homolog)
|
PTEN mutation
|
perifosine (D21266)
7ms
A high-throughput Gaussia luciferase reporter assay for screening potential gasdermin E activators against pancreatic cancer. (PubMed, Acta Pharm Sin B)
Based on this system, ponatinib and perifosine are screened out from the FDA-approved anti-cancer drug library containing 106 compounds. Further, we demonstrate that perifosine suppresses pancreatic cancer by promoting pyroptosis via caspase-3/GSDME pathway both in vitro and in vivo. Collectively, this study reveals the great significance of hGLuc-hGSDME-PCA in identifying compounds triggering GSDME-dependent pyroptosis and developing promising therapeutic agents for PDAC.
Journal
|
CASP3 (Caspase 3) • GSDME (Gasdermin E)
|
Iclusig (ponatinib) • perifosine (D21266)
9ms
Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma. (PubMed, ACS Omega)
We highlighted the therapeutic potential of Epigallocatechin gallate (EGCG), Perifosine, ABT-737, Thymoquinine, Quercetin, Venetoclax, Gefitinib, and Genistein. These compounds are implicated in the therapeutic management of NSCLC. This review further offers deeper mechanistic insights into different signaling pathways that could be targeted for NSCLC therapy by phytochemicals and small-molecule inhibitors.
Review • Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3)
|
Venclexta (venetoclax) • gefitinib • ABT-737 • perifosine (D21266)
11ms
AKT inhibition interferes with the expression of immune checkpoint proteins and increases NK-induced killing of HL60-AML cells. (PubMed, Einstein (Sao Paulo))
The AKT pathway is involved in resistance to natural Killer-induced apoptosis in HL60 cells by regulating the expression of immune suppressor receptors. These findings highlight the importance of AKT in contributing to immune evasion mechanisms in acute myeloid leukemia and suggests the potential of AKT inhibition as an adjunct to immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TNFRSF1A (TNF Receptor Superfamily Member 1A) • CD96 (CD96 Molecule) • LGALS9 (Galectin 9)
|
PD-1 expression • HAVCR2 expression • AKT1 overexpression
|
perifosine (D21266)
12ms
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas (clinicaltrials.gov)
P1, N=10, Completed, Andrew B Lassman, MD | Active, not recruiting --> Completed
Trial completion
|
Torisel (temsirolimus) • perifosine (D21266)
1year
CLU (clusterin) promotes mitophagic degradation of MSX2 through an AKT-DNM1L/Drp1 axis to maintain SOX2-mediated stemness in oral cancer stem cells. (PubMed, Autophagy)
Notably, our results showed that CLU-mediated cytoprotection relies on SOX2 expression. SOX2 inhibition through genetic (shSOX2) and pharmacological (KRX-0401) strategies reverses CLU-mediated cytoprotection, sensitizing oral CSCs towards cisplatin-mediated cell death.
Journal • Cancer stem
|
SOX2 • CLU (Clusterin)
|
SOX2 expression
|
cisplatin • perifosine (D21266)
over1year
Combined BCL-2 and PI3K/AKT Pathway Inhibition in KMT2A-Rearranged Acute B-Lymphoblastic Leukemia Cells. (PubMed, Int J Mol Sci)
Of note, all tested combinations (venetoclax + PI3K inhibitors idelalisib or BKM-120, as well as AKT inhibitors MK-2206 or perifosine) achieved comparable anti-leukemic effects. The present study provides rational combination strategies involving selective BCL-2 and PI3K/AKT inhibition in B-ALL cell lines. Furthermore, we identified a potential mechanistic background of the synergistic activity of combined venetoclax and perifosine application.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • KMT2A (Lysine Methyltransferase 2A) • BBC3 (BCL2 Binding Component 3)
|
KMT2A rearrangement • MLL rearrangement
|
Venclexta (venetoclax) • Zydelig (idelalisib) • MK-2206 • buparlisib (AN2025) • perifosine (D21266)
over1year
Synergistic cytotoxicity of perifosine and ABT-737 to colon cancer cells. (PubMed, J Cell Mol Med)
While the cytotoxicity of single agents was influenced by the tumour-specific microenvironment, perifosine and ABT-737 in combination synergistically induced apoptosis in cells cultured in both 2D and 3D independently on pH and oxygen level. Thus, the combined therapy of perifosine and ABT-737 could be considered as a potential treatment strategy for colon cancer.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1)
|
ABT-737 • perifosine (D21266)
over2years
Tau Regulates Glioblastoma Progression, 3D Cell Organization, Growth and Migration via the PI3K-AKT Axis. (PubMed, Cancers (Basel))
Such a defect in PI3K/AKT signaling was responsible for reduced MCS growth and cell evasion, as demonstrated by the inhibition of the pathway in control MCS using LY294002 or Perifosine, which did not significantly affect Tau-depleted MCS. Finally, analysis of the glioblastoma TCGA dataset showed a positive correlation between the amount of phosphorylated Akt-Ser473 and the expression of MAPT RNA encoding Tau, underlining the relevance of our findings in glioblastoma disease. We suggest a role for Tau in glioblastoma by controlling 3D cell organization and functions via the PI3K/AKT signaling axis.
Journal
|
MAPT (Microtubule Associated Protein Tau)
|
MAPT overexpression
|
LY294002 • perifosine (D21266)
over2years
Neuregulin 2 is highly expressed in glioma tissues to regulate glial fibrillary acidic protein expression via Akt signaling (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)
NRG2 is highly expressed in gliomas of different grades and regulates GFAP expression in glioma cells at least partly via the Akt signaling pathway to affect the survival of glioma patients.
Journal
|
AKT1 (V-akt murine thymoma viral oncogene homolog 1) • GFAP (Glial Fibrillary Acidic Protein)
|
perifosine (D21266)
over2years
PolyI:C suppresses TGF-β1-induced Akt phosphorylation and reduces the motility of A549 lung carcinoma cells. (PubMed, Mol Biol Rep)
PolyI:C has a novel function to suppress the motility of LC cells undergoing EMT by targeting the phosphatidylinositol 3-kinase/Akt pathway partly via PTEN and may prevent or reduce the metastasis of LC cells.
Journal • IO biomarker
|
PTEN (Phosphatase and tensin homolog) • SMAD4 (SMAD family member 4) • CDH1 (Cadherin 1) • TGFB1 (Transforming Growth Factor Beta 1)
|
PTEN expression • CDH1 expression
|
perifosine (D21266)
almost3years
Downregulation of ATXN3 Enhances the Sensitivity to AKT Inhibitors (Perifosine or MK-2206), but Decreases the Sensitivity to Chemotherapeutic Drugs (Etoposide or Cisplatin) in Neuroblastoma Cells. (PubMed, Front Oncol)
Downregulation of ATXN3 enhanced AKT inhibitors (perifosine or MK-2206) induced cell death by BIM, but decreased the cell death induced by chemotherapeutic drugs (etoposide or cisplatin) via Bcl-xl. The expression of ATXN3 may be an indicator in selecting different treatment regimen.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • BCL2L11 (BCL2 Like 11) • ATXN3 (Ataxin 3)
|
BCL2 expression
|
cisplatin • etoposide IV • MK-2206 • perifosine (D21266)
almost3years
Ghrelin Regulates Cyclooxygenase-2 Expression and Promotes Gastric Cancer Cell Progression. (PubMed, Comput Math Methods Med)
After GC AGS cells were handled with ghrelin (10 M), cyclooxygenase-2 inhibitor NS398 (100 μM), and Akt inhibitor perifosine (10uM), the rates of apoptosis were detected by TUNEL assay and flow cytometry assay...Ghrelin increases the expression of COX-2 in GC cells by targeting PI3K/Akt. Ghrelin is suggested to be one of the molecular targets in GC.
Journal
|
AKT1 (V-akt murine thymoma viral oncogene homolog 1) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
|
PTGS2 expression
|
perifosine (D21266)
almost3years
Perifosine enhances the potential antitumor effect of 5-fluorourasil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation. (PubMed, Eur J Pharmacol)
In this study, we investigated the mechanism of the reduced sensitivity of colon cancer cells to 5-fluorouracil (5-FU) and oxaliplatin (L-OHP), and the effects of perifosine, an Akt inhibitor that enhances the cytotoxicity of 5-FU and L-OHP in colon cancer cells harboring the PIK3CA mutation. Perifosine increases the efficacy of 5-FU and L-OHP by suppressing Akt activation. Thus, the use of an Akt inhibitor in combination with 5-FU and L-OHP may be beneficial in colon cancer with cells harboring the PIK3CA mutation.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • BIRC5 (Baculoviral IAP repeat containing 5)
|
PIK3CA mutation • BCL2 expression • TP53 expression • BIRC5 expression
|
5-fluorouracil • oxaliplatin • perifosine (D21266)
3years
Akt Inhibition Enhanced the Growth Inhibition Effects of Low-Dose Heavy-Ion Radiation via the PI3K/Akt/p53 Signaling Pathway in C6 Glioblastoma Cells. (PubMed, Front Oncol)
The growth inhibition effects of low-dose heavy-ion irradiation were not substantial in C6 cells, and Akt inhibition induced by perifosine enhanced the growth inhibition effects via proliferation inhibition, apoptosis, and oxidative stress. Akt inhibition enhanced the effects of heavy-ion radiation, and the PI3K/Akt/p53 signaling pathway may be a critical component involved in the process.
Journal • IO biomarker
|
BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BCL2 expression • TP53 expression • BAX expression
|
perifosine (D21266)
almost4years
Perifosine and vitamin D combination induces apoptotic and non-apoptotic cell death in endometrial cancer cells. (PubMed, EXCLI J)
In TEM examinations of HEC-1A cells, perifosine appeared to lead autophagic cell death, whereas vitamin D caused paraptosis-like cell death and combination of perifosine+vitamin D caused apoptotic and non-apoptotic (paraptotic, autophagic and necrotic) cell death. Therefore, it is considered that the combination of both drugs in the treatment of endometrial cancer might be an alternative and effective treatment option through activating the apoptotic and non-apoptotic cell death mechanisms in cancer cells.
Journal
|
BCL2 (B-cell CLL/lymphoma 2)
|
perifosine (D21266)
4years
Tenascin-C is involved in promotion of cancer stemness via the Akt/HIF1ɑ axis in esophageal squamous cell carcinoma. (PubMed, Exp Mol Pathol)
The Akt inhibitor Perifosine inhibited the protein expression of pAkt-Ser473, Akt, HIF1α, and TNC in TE10 (an ESCC cell line) cells. Short-term exposure of TE10 cells to cobalt chloride caused an increase in protein expression of HIF1α, TNC, and SOX2 in a time-dependent manner. Taken together, these results suggest that TNC may enhance the cancer stem-like properties and promote EMT-like changes via the Akt/HIF1α axis.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • SOX2
|
perifosine (D21266)
over4years
An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway. (PubMed, Biol Open)
Furthermore, the AKT inhibitor perifosine effectively suppressed lapatinib resistance, as indicated by the lapatinib inhibition curve and results of the colony formation assay, and decreased AKT phosphorylation. Altogether, we discovered a procarcinogenic mutation of ERBB2 that enhances BC cell growth through AKT signaling and causes resistance to lapatinib. Patients with this in-frame insertion mutation of ERBB2 should be recommended other therapeutic strategies apart from ERBB2 tyrosine kinase inhibitors, in particular lapatinib.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
lapatinib • perifosine (D21266)
over4years
The Binding of PD-L1 and Akt Facilitates Glioma Cell Invasion Upon Starvation via Akt/Autophagy/F-Actin Signaling. (PubMed, Front Oncol)
Serial truncation identified the interaction between the 128-237aa fragment of PD-L1 and the 112-480aa fragment of Akt, which facilitates the membrane translocation/activation of Akt, and was unaffected by Perifosin (specific p-Akt inhibitor targeting Akt PH-domain). Taken together, our data indicate that in glioma cells, PD-L1 is induced to prevent autophagic cytoskeleton collapse via Akt binding/activation, facilitating glioma cell invasion upon starvation stress.
Journal • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1)
|
perifosine (D21266)